The Effects of Covid-19 Pandemic on The Patients With Fibromyalgia

Diskapi Yildirim Beyazit Training and Research Hospital

Status: Unknown

Conditions: Covid-19 Anxiety; Fibromyalgia; Daily Life; Anxiety Depression; Sleep Quality; Covid-19 Fear

Study type: Observational

Funder types: Other

Identifiers

NCT04686578

Fibromyalgia-pandemi

Details and patient eligibility

About

The investigators planned to analyze the effect of Covid-19 fear and anxiety on the daily life, sleep quality and depression-anxiety levels of fibromyalgia patients.

Full description

Fibromyalgia; as a chronic syndrome of unknown cause with widespread body pain, fatigue, sleep disorder, cognitive impairment and anxiety. Many studies have shown a relationship between pain levels and anxiety levels in patients with fibromyalgia. Covid-19 started from Wuhan, China in December 2019 and spread worldwide. The rapid spread of this unexpected pandemic all over the world brought with it many conditions such as anxiety and stress disorders. It has been reported by experts that individuals with a predisposition to conditions such as anxiety and stress disorder in premorbidity require special attention.To evaluate the psychological effects of the Covid-19 pandemic, the Covid-19 anxiety scale was developed from Lee et al. and the Covid-19 fear scale was developed from Ahoursou et al. The investigators planned to analyzed the effect on Covid-19 fear and anxiety level on fibromyalgia patients' daily life with revised Fibromyalgia Impact questionnaire, sleep quality with Pittsburgh Sleep Quality Index, and anxiety-depression level with The Hospital Anxiety and Depression scale. This study was planned as a cross-sectional case control study.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (Fibromyalgia group):

• Patients diagnosed as Fibromyalgia syndrome according to American College of Rheumatology over 1 year
• Patients' disease activity is stabil at least 3 months Inclusion Criteria (Control group) Patients have no physicologic or severe musculoskeletal and rheumatologic diseases

Exclusion Criteria:

• Patients with having other modd disorders
• Patients with severe musculoskeletal diseases
• Patients with other rheumatologic diseases

Trial design

100 participants in 2 patient groups

Fibromyalgia group

Description:

Diagnosed as Fibromyalgia according to American College of Rheumatology Fibromyalgia 2018 classification criteria over 1 year, and disease activity was stabil with the same drug at least 3 months.

Control Group

Description:

The participants who have no physicological or severe musculoskeletal, rheumatologic diseases.